It has been reported that this new option could exert profound cytotoxicity against Ph+ ALL cell lines and that its killing effects do not impart by resistance mutations in BCR-ABL1-kinase domain (29). The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.